Navio MD Review
Best for: compounded tirzepatide with brand-name fallback across 48 states
NavioMD offers compounded tirzepatide ($247/mo) plus brand-name Ozempic ($1,199/mo) and Mounjaro ($1,249/mo). LegitScript verified. Available in 48 states (not AL or MS). Same price at every dose. Also offers women's hormone optimization.
High confidence · Last verified 2026-04-10 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Navio MD is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compound Tirzepatide | compounded | $247 |
| Ozempic | brand | $1199 |
| Mounjaro | brand | $1249 |
✓ Pros
- •LegitScript verified with board-certified providers and US-licensed pharmacies
- •Same price at every dose — no price escalation
- •Both compounded and brand-name options
- •48-state coverage
- •Hours 9am–10pm EST Mon–Sun
✗ Cons
- •Not available in Alabama and Mississippi
- •Compounded option is tirzepatide only — no compounded semaglutide listed
- •Brand-name at near-retail pricing ($1,199–$1,249/mo)
- •Also offers women's HRT (broader platform)
Ready to start with Navio MD?
Starting at $247/month. See current pricing and start your free consultation.
Sources & methodology
Our Navio MD review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Navio MD
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Navio MD?
Starting at $247/month. See current pricing and start your free consultation.